Skip to main content

Table 2 Efficacy endpoints

From: Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer

Endpoint

Results

Median time to progression second-line trastuzumab-based therapy (months)

7 (95% CI 5.74-8.26)

Median time to progression first-line trastuzumab-based therapy (months)

8 (95% CI 6.26-9.74)

Overall survival (months)

43 (95% CI 37,92-48.09)

Response rate second-line trastuzumab-based therapy (%)

30.9%

Complete response (%)

7.2%

Partial response (%)

23.7%

Response rate first-line trastuzumab-based therapy (%)

44.3%

Complete response (%)

9.3%

Partial response (%)

35.1%

Clinical Benefit second-line trastuzumab-based therapy (%)

66%

Clinical Benefit first-line trastuzumab-based therapy (%)

83.5%

Time to development of brain metastases (months)

21 (95% CI 13.86-28.14)

Overall survival after treatment for brain metastases (months)

10 (95% CI 4.53-15.47)

Drop of left ventricular ejection fraction (LVEF) > 10% (n=)

3

Symptomatic congestive heart failure (n=)

2